Stay updated with breaking news from Tom Graney. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Leuven, BELGIUM, Boston, MA, US - MARCH 3, 2022 - 08:00 AM CET - Oxurion NV (Euronext Brussels: OXUR) (the "Company" or "Oxurion"), a biopharmaceutical company developing next generation
OXURION SUCCESSFULLY RAISES EUR >10 MILLION FROM LEADING US AND EUROPEAN HEALTHCARE INVESTORS IN A PRIVATE EQUITY PLACEMENT3 Mar 2022Leuven, BELGIUM, Boston, MA, US - MARCH 3, 2022 – 08:00 AM CET – Oxurion NV (Euronext Brussels: OXUR)(the "Company" or "Oxurion"), a bioph...
Oxurion Announces New Data on THR-149 Phase 2 Clinical Trial (“KALAHARI”) in DME at the Angiogenesis, Exudation, and Degeneration 2022 Conference Post-hoc analysis reveals >9 letter gain in mean BCVA that was maintained for the remaining four months of the trial after the last THR-149 injection w...
Post-hoc analysis reveals >9 letter gain in mean BCVA that was maintained for the remaining four months of the trial after the last THR-149 injection with no rescue treatment requiredThese gains were seen
Leuven, BELGIUM, Boston, MA, US - January 18, 2022 - 08.00 AM CET - Oxurion NV(Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic